| Literature DB >> 22257757 |
Yolanda D Sheppard1, Dean Middleton, Yvonne Whitfield, Felix Tyndel, Shariq Haider, Jamie Spiegelman, Richard H Swartz, Mark P Nelder, Stacey L Baker, Lisa Landry, Ross Maceachern, Sherri Deamond, Lorrie Ross, Garth Peters, Michelle Baird, David Rose, Greg Sanders, John W Austin.
Abstract
Five cases of intestinal toxemia botulism in adults were identified within an 18-month period in or near Toronto, Ontario, Canada. We describe findings for 3 of the 5 case-patients. Clinical samples contained Clostridium botulinum spores and botulinum neurotoxins (types A and B) for extended periods (range 41-61 days), indicative of intestinal toxemia botulism. Patients' clinical signs improved with supportive care and administration of botulinum antitoxin. Peanut butter from the residence of 1 case-patient yielded C. botulinum type A, which corresponded with type A spores found in the patient's feces. The food and clinical isolates from this case-patient could not be distinguished by pulsed-field gel electrophoresis. Two of the case-patients had Crohn disease and had undergone previous bowel surgery, which may have contributed to infection with C. botulinum. These cases reinforce the view that an underlying gastrointestinal condition is a risk factor for adult intestinal toxemia botulism.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22257757 PMCID: PMC3310098 DOI: 10.3201/eid1801.110533
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
FigureResults of pulsed-field gel electrophoresis of samples from case-patient 1, who had intestinal toxemia botulism, Ontario, Canada, 2006–2008. Lanes 1, 3: Clostridium botulinum type A isolated from enema sample; lanes 2, 4: C. botulinum type A isolated from peanut butter obtained from residence of patient. Samples in lanes 1 and 2 were digested with SmaI; samples in lanes 3 and 4 were digested with XhoI.
Clinical summary of 3 intestinal toxemia botulism cases in adults, Ontario, Canada, 2006–2008
| Case-patient no. | Age, y/sex | Dates admitted to hospital and discharged | Clinical findings | Gastrointestinal history | No. days stool sample positive for | Supportive care; antitoxin; administration date | |
|---|---|---|---|---|---|---|---|
| 1 | 63/F | 2006 Nov 22 | Abdominal pain, diarrhea, dysphagia, diplopia, weakness | Crohn disease, short bowel syndrome, remote bowel surgery | A | 61 | Intubation and ventilation; bivalent type A and B, monovalent type E; 2006 Nov 23 |
| 2 | 50/F | 2007 Feb 8; 2007 Sep | Dysphagia, double vision, weakness, difficulty breathing | Crohn disease, bowel resections | A and B | 56 | Intubation and ventilation; bivalent type A and B, monovalent type E; 2007 Feb 23 |
| 3 | 45/M | 2008 Jan 8; 2008 Feb 27 | Abdominal distension and obstruction, aphonia, diplopia, dry mouth, dysphagia, dysphonia, ptosis | Unremarkable | B | 41 | Bivalent type A and B, monovalent type E; 2008 Jan 14 |
*Total number of days that C. botulinum spores or neurotoxins were detected in clinical samples.
| 1. The activity supported the learning objectives. | ||||
| Strongly Disagree | Strongly Agree | |||
| 1 | 2 | 3 | 4 | 5 |
| 2. The material was organized clearly for learning to occur. | ||||
| Strongly Disagree | Strongly Agree | |||
| 1 | 2 | 3 | 4 | 5 |
| 3. The content learned from this activity will impact my practice. | ||||
| Strongly Disagree | Strongly Agree | |||
| 1 | 2 | 3 | 4 | 5 |
| 4. The activity was presented objectively and free of commercial bias. | ||||
| Strongly Disagree | Strongly Agree | |||
| 1 | 2 | 3 | 4 | 5 |